Corcept Accounts Payable from 2010 to 2024

CORT Stock  USD 57.54  1.62  2.90%   
Corcept Therapeutics Accounts Payable yearly trend continues to be comparatively stable with very little volatility. Accounts Payable is likely to outpace its year average in 2024. Accounts Payable is the amount Corcept Therapeutics Incorporated owes to suppliers or vendors for products or services received but not yet paid for. It represents Corcept Therapeutics' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2000-12-31
Previous Quarter
19.5 M
Current Value
18.6 M
Quarterly Volatility
4.5 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Corcept Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Corcept Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 4.3 M, Selling General Administrative of 193.1 M or Research Development of 193.6 M, as well as many indicators such as Price To Sales Ratio of 6.62, Dividend Yield of 0.0 or PTB Ratio of 6.97. Corcept financial statements analysis is a perfect complement when working with Corcept Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Corcept Therapeutics Correlation against competitors.

Latest Corcept Therapeutics' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Corcept Therapeutics Incorporated over the last few years. An accounting item on the balance sheet that represents Corcept Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Corcept Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Corcept Therapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Corcept Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Corcept Accounts Payable Regression Statistics

Arithmetic Mean6,990,053
Geometric Mean4,169,112
Coefficient Of Variation80.96
Mean Deviation4,485,790
Median6,908,000
Standard Deviation5,659,081
Sample Variance32T
Range18.2M
R-Value0.88
Mean Square Error7.5T
R-Squared0.78
Significance0.000012
Slope1,119,424
Total Sum of Squares448.4T

Corcept Accounts Payable History

202418.3 M
202317.4 M
202212 M
20216.9 M
202010.6 M
20197.5 M
20188.3 M

About Corcept Therapeutics Financial Statements

Corcept Therapeutics shareholders use historical fundamental indicators, such as Accounts Payable, to determine how well the company is positioned to perform in the future. Although Corcept Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Corcept Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Corcept Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Accounts Payable17.4 M18.3 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Corcept Stock Analysis

When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.